EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Duvyzat (givinostat) as a treatment for Duchenne muscular dystrophy (DMD) in patients from the age of six who are able to walk. Duvyzat is an oral suspension to be taken at the same time as corticosteroid treatment.
DMD is a rare genetic disease caused by a lack of dystrophin, a protein that helps strengthen muscle fibres and protect them from injury as muscles contract. This causes the muscles to progressively weaken and lose function and is ultimately lethal. This process is worsened by increased levels of histone deacetylases (HDAC), a class of proteins…
